• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutics and Clinical Risk Management >Dose-independent influence of metoprolol on cardiac and motor functions, QoL, and mental status in Chinese patients with CHF
【24h】

Dose-independent influence of metoprolol on cardiac and motor functions, QoL, and mental status in Chinese patients with CHF

机译：美托洛尔对中国CHF患者心动功能，生活质量和精神状态的剂量依赖性影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The objective of the study was to evaluate the dose-related influence of metoprolol on cardiac performance, motor function, quality of life (QoL), and mental status in Chinese patients with chronic heart failure (CHF). Patients and methods: This was a prospectively designed single-center study which enrolled CHF patients with resting heart rate (HR) 80 bpm belonging to the New York Heart Association (NYHA) III/IV functional classification. Patients were initiated with 12.5 mg of metoprolol, and every second week, the dose was escalated until the target HR level (60–70 bpm) was achieved during the follow-up at 1st, 3rd, 6th, and 12th months. Patients were divided into two groups depending on the doses administered: 47.5 mg (n=37) and 118.75 mg (n=74), respectively, for comparison in terms of change in cardiac function, motor function, QoL, and mental status. Results: Among the 111 patients with CHF, no significant difference was shown between the two doses administered. Irrespective of the dose, the cardiac performance, motor function, QoL, and anxiety improved and there was an increase in depression, whereas the effect on burnout, calculated as Copenhagen Burnout Inventory (CBI), equally was insignificant throughout the 1-year follow-up period in both the CHF patient groups. Conclusion: Lower dose of metoprolol (47.5 mg) is as effective as higher dose (118.75 mg) in Chinese population with CHF to improve the cardiac function, motor function, QoL, and mental status.
机译：目的：本研究的目的是评估美托洛尔对中国慢性心力衰竭（CHF）患者的心脏性能，运动功能，生活质量（QoL）和精神状态的剂量相关影响。患者和方法：这是一项前瞻性设计的单中心研究，纳入了静息心率（HR）> 80 bpm的CHF患者，属于纽约心脏协会（NYHA）III / IV功能分类。患者开始使用12.5 mg美托洛尔，并且每隔2周逐步增加剂量，直到在随访的第1、3、6和12个月达到目标HR水平（60-70 bpm）。根据给药剂量将患者分为两组：分别用于心功能，运动功能，生活质量和精神状态变化方面的比较，分别为47.5 mg（n = 37）和118.75 mg（n = 74）。结果：在111例CHF患者中，两次给药之间没有显着差异。不论剂量如何，心脏性能，运动功能，生活质量和焦虑感都会得到改善，抑郁感会增加，而对倦怠的影响（以哥本哈根倦怠量表（CBI）计算）在整个1年随访中均无统计学意义。两个瑞士法郎患者组都处于活跃期。结论：在中国患有CHF的人群中，较低剂量的美托洛尔（47.5 mg）与较高剂量（118.75 mg）一样有效，可改善心脏功能，运动功能，生活质量和精神状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号